These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 723839)

  • 1. Lymphokine preparations: a new approach to cancer immunotherapy.
    Papermaster BW; Kaltenbach ML
    Mo Med; 1978 Dec; 75(12):607-9, 612. PubMed ID: 723839
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunochemotherapy of human cancer.
    Gutterman JU; Mavligit GM; Reed RC; Hersh EM
    Semin Oncol; 1974 Dec; 1(4):409-23. PubMed ID: 4620443
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
    Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
    Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
    [No Abstract]   [Full Text] [Related]  

  • 4. Lymphokine-mediated immunotherapy studies in mouse tumor systems.
    Papermaster BW; Gilliland CD; McEntire JE; Smith ME; Buchok SJ
    Cancer; 1980 Mar; 45(5 Suppl):1248-53. PubMed ID: 7357517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correspondence re: J. H. Pincus, A. K. Jameson, and A. E. Brandt. Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy. Cancer Res., 41: 3082-3086, 1981.
    Brandt AE
    Cancer Res; 1982 Oct; 42(10):4263-4. PubMed ID: 7105020
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity of modified tumor cells in syngenic hosts.
    Prager MD; Gordon WC; Baechtel FS
    Ann N Y Acad Sci; 1976; 276():61-74. PubMed ID: 1071980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular engineering of the antitumor immune response.
    Pardoll DM; Golumbek P; Levitsky H; Jaffee L
    Bone Marrow Transplant; 1992; 9 Suppl 1():182-6. PubMed ID: 1387016
    [No Abstract]   [Full Text] [Related]  

  • 9. Experimental models and the role of RNA in immunotherapy of leukemia.
    Ono R; Esaki K; Kodera Y; Shiku H; Yamada K
    Ann N Y Acad Sci; 1973 May; 207():430-41. PubMed ID: 4517719
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E; Chriqui-Zeira E; Kyriazis AP
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

  • 12. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.
    Mathé G; Kamel M; Dezfulian M; Halle-Pannenko O; Bourut C
    Cancer Res; 1973 Sep; 33(9):1987-97. PubMed ID: 4146853
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy.
    Pincus JH; Jameson AK; Brandt AE
    Cancer Res; 1981 Aug; 41(8):3082-6. PubMed ID: 7248965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immunotherapy in spontaneous leukemia of AkR mice.
    Mathé G; Halle-Pannenko O; Bourut C
    Exp Hematol; 1973; 1(2):110-4. PubMed ID: 4609352
    [No Abstract]   [Full Text] [Related]  

  • 15. Parameters of serum complement in relation to tumor therapy.
    Drake WP; Mardiney MR
    Biomedicine; 1974 May; 21(5):206-9. PubMed ID: 4433667
    [No Abstract]   [Full Text] [Related]  

  • 16. An experimental model for immunotherapy of cancer.
    Zbar B; Ribi E; Rapp HJ
    Natl Cancer Inst Monogr; 1973 Dec; 39():3-9. PubMed ID: 4595326
    [No Abstract]   [Full Text] [Related]  

  • 17. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
    Nicolin A; Canti G; Goldin A
    Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
    [No Abstract]   [Full Text] [Related]  

  • 18. Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease.
    Poste G; Kirsh R
    Prog Clin Biol Res; 1982; 102 pt A():309-19. PubMed ID: 7167443
    [No Abstract]   [Full Text] [Related]  

  • 19. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G; Halle-Pannenko O; Bourut C
    Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: Routes other than I.V. injection to mice for BCG administration in active immunotherapy of L1210 leukemia.
    Martin M; Bourut C; Halle-Pannenko O; Mathé
    Biomedicine; 1975 Oct; 23(8):339-40. PubMed ID: 1231929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.